March/April issue of HTB now online

5 April 2012. Related: News.

The March/April edition of HIV Treatment Bulletin is now online.

This issue largely features our first coverage from the Conference of Retroviruses and Opportunistic Infections (CROI), which this year attracted over 4000 delegates to Seattle.

Much of the conference is available as web casts and references in HTB also link to the study abstracts. Further coverage will continue in the next issue, with pre-press articles available online.

Read HTB online.

Download PDF version.

CONTENTS

Editorial

• Volume 13 Number 3/4 March/April 2012

Special reports

• Supplement: i-Base Introduction to Combination Therapy

Conference reports

• 19th Conference on Retroviruses and Opportunistic Infections (CROI), 5–8 March 2012, Seattle

• Cure research takes centre stage: proof of concept for activating the latent reservoir

• Quad fixed-dose integrase combination: phase 3 studies at week 48

• Dolutegravir studies continue to show promise

• Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation

• Paediatric formulations of ARVs: including an exciting new class

• Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART

• High prevalence of d4T-associated lipodystrophy including lipoatrophy in children

• Lopinavir/ritonavir monotherapy in children

• Stopping treatment after early ART in infants

• PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection

• Risk of HIV reinfection may be similar to risk of initial HIV infection

• Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus

• No association between atazanavir and MI or stroke in D:A:D study

• Hepatitis C coinfection studies

• Herpes Zoster vaccine safe and effective in HIV positive people

• High dose flu vaccine improves antibody responses in HIV positive people

Antiretrovirals

• Dolutegravir Expanded Access Programme

• FDA approves etravirine for treatment-experienced children 6 to 18 years of age and new scored 25 mg tablet for paediatric dosing

Guidelines

• US HHS adult treatment guidelines updated (March 2012)

Side effects

• FDA reject capsaicin patch for HIV-related neuropathy

PK and drug interactions

• FDA warning of drug interactions between boceprevir and some HIV protease inhibitors

Treatment access

• Global action over the challenge to India’s patent laws

• Why global health activists are fired up about Novartis

• Obama’s global, domestic & HIV research budget backslides on existing commitments

Other news

• Free comic book for HIV positive children about CD4, viral load and ARV treatment

On the web

• Free full text online articles

PDFs

• Volume 13 Number 3/4 March/April 2012 PDF